Photodynamic Therapy for Glioblastoma Multiforme Based on Metaverse and Yellow Fluorescence

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorZhejiang Provincial People's Hospital

About this trial

GBM patients receiving PDT treatment (50 cases,surgery combined with photodynamic therapy) and traditional treatment (50 cases,traditional surgery) in our hospital and partner hospitals were collected. The prognosis was analyzed by comparing with the control group from multiple perspectives such as image evaluation, imaging effect, Karnofsky score, median survival time and survival rate.

Eligibility criteria

Qualifiers

None

Disqualifiers

Photosensitizer allergy.

Severe coagulation disorder.

Patients with severe cardiovascular and cerebrovascular diseases, especially patients in the acute stage.

Multiple organ failure, end-stage patients. ⑤ Pregnant women: Photofrin is considered a class C pregnancy risk (toxic, non-teratogenic) drug with non-dialysis properties.

Trial design

Treatments tested in this trial

  • Photodynamic therapy (PDT)
  • GBM patients recevied traditional treatment options

Treatment groups

100 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Zhejiang Provincial People's Hospital

Lead sponsor

The Second Affiliated Hospital of Harbin Medical University

Collaborator